Genta/Aventis Genasense Rolling NDA Submission Will Be Completed In Q4
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Genta’s Phase III Genasense results should be enough to gain FDA approval for treatment of malignant melanoma despite the lack of a statistically significant improvement in survival in the intent to treat population, the firm told a Sept. 10 conference call.